Navigation Links
Studies point to novel target for treating arrhythmias
Date:1/21/2009

Abnormal heart rhythms arrhythmias are killers. They strike without warning, causing sudden cardiac death, which accounts for about 10 percent of all deaths in the United States.

Vanderbilt investigators have discovered a new molecular mechanism associated with arrhythmias. Their findings, reported in The Journal of Clinical Investigation, could lead to novel arrhythmia treatments.

"The current antiarrhythmic drugs do not prolong life," said Bjrn Knollmann, M.D., Ph.D., associate professor of Medicine and Pharmacology and the senior author of the current report. "There's a large need for new approaches to antiarrhythmic therapy."

In their quest to understand how irregular heart rhythms arise as a way to find new molecular targets for treatment Knollmann and his colleagues have focused on the role of calcium inside heart muscle cells.

Calcium is central to the contractile cycle. After it is released from its storage sites in heart muscle cells, it interacts with proteins called troponins, part of the cell's myofilament contractile apparatus. The interaction of calcium with troponins regulates myofilament activation and contraction.

Mutations in troponin genes had been linked to inherited forms of hypertrophic cardiomyopathy (HCM), which carries a high risk of sudden cardiac death. HCM is perhaps most famous as a cause of sudden cardiac death in young athletes, but it can affect individuals of any age.

In previous studies, Knollmann's team demonstrated that troponin mutations associated with HCM increase the sensitivity of the troponins to calcium they bind calcium more readily, which activates the myofilaments more easily and results in stronger contractions.

Increased myofilament calcium sensitivity has also been found in acquired heart diseases, such as heart failure, that have a high incidence of sudden cardiac death, Knollmann said. He and his colleagues proposed that increased myofilament calcium sensitivity contribut
'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Studies examine genetic determinants of ADHD
2. Studies offer guide as protein interaction mapping comes of age
3. Web-based case studies help students develop career skills
4. To improve forecasting earthquakes, NJIT mathematician studies grains
5. Studies on imaging and tracking transplanted cells
6. UI researchers help to improve carbon measurements in global climate studies
7. MSU researcher studies ties between cholesterol drugs, muscle problems
8. Studies of small water fleas help ecologists understand population dynamics
9. ASU researchers receive NIH awards for studies of malaria and emergent disease
10. Drug-embedded microparticles bolster heart function in animal studies
11. NIAID funds studies of how SARS and bird flu evade antiviral responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... A new study compares the relative rate of molecular evolution ... wanted to know whether evolution marches on at a steady pace ... of individual letters of the genetic code occur more rapidly ... study appears in the Proceedings of the Royal Society B ...
... Ga. - A well-documented suppressor of immunity that,s used ... to change its spots, researchers report. In the ... 2,3-dioxegenase, or IDO, also appears capable of helping key ... the invader, said Dr. Tracy L. McGaha, immunologist at ...
... 7, 2014   Dynasil Corporation of America ("Dynasil" ... developer of sensing, detection and analysis technology for homeland ... has regained compliance with the $1.00 minimum bid price ... As previously announced, on March 26, 2013, ...
Cached Biology News:Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3Finding about classic suppressor of immunity points toward new therapies for bad infections 2Finding about classic suppressor of immunity points toward new therapies for bad infections 3Dynasil Regains Compliance with NASDAQ Listing Requirements 2
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... ... 2015 , ... The 2015 Market Research Report on the Global Propanol ... global Propanol market with a focus on the Chinese situation. Major companies included in ... ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... provide a,sensitive method to detect protease activity, measure ... of drug candidates. LI-COR,Biosciences now offers three different ... BACE, and IRDye 800CW/QC-1 CSP-3., "These substrates ... conjugated dye by our novel IRDye QC-1 quencher," ...
... Studies show that up to 30% of coffees ordered as ,decaf, ... ... Ever wonder whether the,coffee you had after dinner was really decaf? ... caffeine test strip from,Silver Lake Research, the leader in at-home water quality ...
... today that Gemstone Acquisition Corporation, a wholly-owned,subsidiary of ... purchase all,outstanding shares of common stock of Genelabs ... interest and less any required withholding,taxes. The tender ... announced,Agreement and Plan of Merger dated October 29, ...
Cached Biology Technology:LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates 2Is Your Decaf Really Decaf? 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... with Annexin V-FITC to distinguish cells that ... (Annexin V positive, PI negative) from those ... or already dead (Annexin V-FITC positive, PI ... range of the spectrum using a 562-588 ...
... Mouse A-20 cells were cultured in RPMI ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: